References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
Research buyers comparing product options may also review the standard Reta product and the Reta pen formats
Consider Fermented Foods A healthy gut microbiome is linked to higher natural GLP-1 production
Injecting into muscle rather than fat can alter drug absorption and increase the risk of pain or bruising
This article explains why GLP-1 medications alone often fail to produce sustainable weight loss, highlighting muscle loss, metabolic adaptation, and weight regain, and emphasizing a metabolism-first approach
Taher J, Baker CL, Cuizon C, Masoudpour H, Zhang R, Farr S, et al